Fairmount Healthcare Fund II L.P., an investment vehicle affiliated with a director of Spyre Therapeutics, Inc. (NASDAQ: SYRE), executed a substantial liquidation of equity in the biotechnology company on June 23, 2026. The fund sold 4,684,781 shares of common stock, realizing a total transaction value of $399,658,667. The shares were divested at a price of $85.31 per unit. This notable transaction follows the conversion of Series B Preferred Stock into common equity by the same fund on the same date.
Transaction Details and Ownership Structure
The divestment activity was preceded by the conversion of 16,667 shares of Series B Preferred Stock into 666,680 shares of common stock. This conversion process occurred without cash consideration, operating under a fixed ratio where each share of Series B Preferred Stock is convertible into 40 shares of common stock. These conversion rights are subject to specific beneficial ownership limitations. Following the execution of the sale, Fairmount Healthcare Fund II L.P. holds no remaining common stock from this specific transaction.
Fairmount Healthcare Fund II L.P. is managed by Fairmount Funds Management LLC. Peter Harwin and Tomas Kiselak serve as managers for Fairmount Funds Management LLC. Tomas Kiselak also holds a position on the board of directors of Spyre Therapeutics, Inc., and is classified as a director by deputization. In accordance with regulatory standards, Fairmount Funds Management LLC, Mr. Harwin, and Mr. Kiselak have disclaimed beneficial ownership of the reported securities, except to the extent of their pecuniary interest.
Despite the liquidation of common shares, Fairmount Healthcare Fund II L.P. continues to maintain a significant position in preferred equity. The fund holds 346,045 shares of Series A Preferred Stock. These shares carry conversion rights into 13,841,800 shares of common stock at a 40-to-1 ratio, also subject to beneficial ownership limitations. Separately, Tomas Kiselak and Peter Harwin each indirectly hold 406,038 shares of Spyre Therapeutics common stock.
Market Valuation and Price Action
The timing of the sale presents a distinct valuation context. Spyre's stock has since climbed to $97.05, representing a 13.8% gain above the $85.31 sale price. According to InvestingPro data, the stock is currently trading near its 52-week high of $102.06. Valuation metrics suggest the stock appears overvalued based on Fair Value analysis, placing it among candidates for the Most Overvalued stocks list. The stock exhibits high volatility, with a Beta of 3.06, and has delivered an impressive 530% return over the past year.
Recent price action indicates continued market interest. The stock closed at 97.05, reflecting a decline of 3.270 or 3.26%. After-hours trading showed a further adjustment, with the stock trading at 89.37, down 7.680 or 7.91%.
Clinical Developments and Capital Raising
Spyre Therapeutics has reported significant progress in its clinical pipeline. The company announced that its experimental drug, SPY002, achieved the primary endpoint in a Phase 2 trial for moderately-to-severely active ulcerative colitis. The trial, known as SKYLINE, demonstrated a 10.7-point reduction in Robart's Histopathology Index score at week 12, indicating a significant improvement in patients' conditions.
Additionally, Spyre has completed enrollment for its SKYWAY basket trial evaluating SPY072 in rheumatic diseases. Data from this trial is expected in 2026. On the capital markets front, Spyre completed a public offering of 7,475,000 shares at $62.00 each, raising approximately $463.5 million.
Analyst Perspectives
Major investment banks have adjusted their outlooks on Spyre Therapeutics following recent developments. Deutsche Bank raised its price target for Spyre to $115, maintaining a Buy rating. This adjustment followed a setback for competitor Abivax. Similarly, Stifel increased its price target to $107, also maintaining a Buy rating. Stifel cited strong data for SPY001 in ulcerative colitis as a key driver for the upgrade. These developments mark significant progress and interest in Spyre's ongoing projects and financial strategies.